{
  "id": "5a9ac7ba1d1251d03b000013",
  "type": "factoid",
  "question": "What does intepirdine target?",
  "ideal_answer": "Intepiridine is a 5-HT6 antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28253832"
  ],
  "snippets": [
    {
      "text": "The 5-HT-6 receptor antagonists Idalopirdine and Intepirdine have shown the most progress in current clinical trials and warrant consideration as emerging treatments for AD. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review discusses 5-HT6 antagonists currently in clinical trials as potential treatments for AD symptomatology and how 5-HT6 physiology may play a positive role in alleviating AD symptom pathophysiology. A literature search using PubMed was conducted using the terms Idalopirdine, Intepirdine, 5-HT-6 antagonist, and AD as keywords. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "If current Phase-3 trials are positive, 5-HT6 antagonists such as Idalopirdine and Intepirdine may be considered as supplementary treatments to ChEI's and NMDA receptor antagonists for the symptomatic treatment of AD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28253832",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "5-HT6"
}